Why the study?
Does 18F-FDG PET accurately characterize malignancy in patients with adrenocortical tumors compared to CT and iodocholesterol scintigraphy?
Population
13 consecutive patients with an adrenal mass scheduled to have surgery, without known neoplastic disease and…
Comparison
18F-fluorodeoxyglucose positron emission… vs Computed tomography scanning and iodocholesterol…
Design
Case_series
Authors
Loading...
May differentiate adrenocortical carcinoma from benign lesions on 18F-FDG PET; hypothesis-generating and requires larger prospective validation.
Does 18F-FDG PET accurately characterize malignancy in patients with adrenocortical tumors compared to CT and iodocholesterol scintigraphy?
18F-FDG PET may accurately differentiate malignant from benign adrenocortical lesions, though larger confirmatory studies are needed.
Tenenbaum et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: